These diabetes devices are set to launch in 2024

The Stelo glucose monitor. [Image courtesy of Dexcom]The diabetes space continues to innovate and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year.

At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year. Some of those stories didn’t end in 2023, though, as a few major product launches loom on the horizon.

New CGMs, insulin pumps and combinations of the two will all be coming to the market over the next several months. Here are some of the most highly-anticipated product launches set to take place in the diabetes space in 2024 — plus some of the tech that’s already launched:

Diabetes launches on the horizon Medtronic’s new pump-sensor combo

In January, Medtronic won CE mark for its MiniMed 780G automated insulin delivery system with the Simplera Sync sensor.

The MiniMed 780G with the Simplera Sync CGM and accompanying devices. [Image courtes…
Read more
  • 0

The 10 biggest diabetes tech stories from 2023

Medtronic, EOFlow, Dexcom, Beta Bionics and Tandem Diabetes Care all contributed some of the biggest diabetes technology stories of 2023.

It was another banner year for diabetes technology, with regulatory approvals, product launches and M&A all playing their part.

Diabetes technology’s impressive 12 months marked a major trend across medtech as a whole, too.

In 2022, the diabetes space saw plenty of progress from some of its biggest names and this past year proved no different. Big hitters like Dexcom, Abbott, Medtronic, Insulet and more all contributed to some of the biggest stories in 2023. External factors — like popular GLP-1 drugs and big tech names looking to enter the space — also made the cut.

Here are 10 of the most intriguing diabetes technology stories from the past 12 months.

Medtronic was set to buy EOFlow — until it wasn’t

The medtech giant made a big splash in the insulin delivery space when it announced its plan to buy South K…

Read more
  • 0

Beta Bionics integrates iLet bionic pancreas with Dexcom G7

The iLet bionic pancreas and the Dexcom G7 CGM. [Image courtesy of Beta Bionics]Beta Bionics announced today that it began the U.S. launch of its iLet bionic pancreas with the Dexcom G7 continuous glucose monitor (CGM).

The launch marks the second G7-compatible automated insulin delivery system to hit the market in as many days. Yesterday, Tandem Diabetes Care became the first to launch an artificial pancreas using Dexcom’s next-generation CGM technology.

With a firmware update, users can update their iLet to integrate with the Dexcom G7 with no additional cost for new hardware.

To upgrade, users can download or update their iLet app on the Apple App Store or Google Play Store, available Dec. 18. Once updated, they can change the firmware on their iLet bionic pancreas and select their CGM. Other features help to streamline the setup process as well.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Beta Bionics earns pharmacy benefit win for bionic pancreas

The iLet Bionic Pancreas with a Dexcom G6 CGM and Convatec infusion set. [Image courtesy of Convatec/Beta Bionics]Beta Bionics announced that Express Scripts added its iLet bionic pancreas and associated supplies to its commercial national formulary offerings.

The decision enables faster and easier access to iLet for eligible users with plans that cover the system under their pharmacy benefit. It marks more good news for Beta Bionics, which closed a $100 million funding round a few months ago.

Historically, insulin pumps fall under the durable medical equipment (DME) insurance benefit. This can lead to significant up-front hardware costs to initiate therapy. Coverage under a pharmacy benefit can reduce the potentially large upfront cost of the pump for the patient and payer. The company said this allows patients to upgrade their insulin pump when new technology becomes available.

Concord, Massachusetts-based Beta Bionics designed its iLet autonomous insulin…

Read more
  • 0

Beta Bionics closes $100M Series D to support bionic pancreas

The iLet Bionic Pancreas with a Dexcom G6 CGM and Convatec infusion set. [Image courtesy of Convatec/Beta Bionics]Beta Bionics announced that it successfully closed a Series D funding round, securing $100 million in new equity capital.

Concord, Massachusetts-based Beta Bionics develops its flagship iLet bionic pancreas. The autonomous insulin delivery system streamlines diabetes management and reduces the burden on patients and physicians. iLet received FDA clearance in May.

While Beta Bionics did not list an intended use of proceeds, the Series D funds could go toward commercialization efforts for iLet.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

8 drug delivery innovations you should know

Innovations in drug delivery never stop and, over the past 12 months or so, a wide variety have come under the spotlight.

Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing just how many ways we can deliver therapeutics.

About a year ago, we clued in readers to a list of six drug delivery innovations they should know. Here, we provide a couple of updates on those and try to introduce a few more developments that you should know:

The latest in automated insulin delivery tech

Automated insulin delivery represents one of the most high-profile markets in drug delivery, with the technology providing potentially life-saving therapy for people with diabetes.

The Mobi automated insulin pump with the accompanying mobile app. [Image courtesy of Tandem Diabetes Care]Last year’s roundup included the already FDA-cleared Omn…
Read more
  • 0

Convatec, Beta Bionics partner on iLet bionic pancreas

The iLet Bionic Pancreas with a Dexcom G6 CGM and Convatec infusion set. [Image courtesy of Convatec/Beta Bionics]Convatec announced that it partnered with Beta Bionics on the launch of the iLet Bionic Pancreas for automated insulin delivery.

FDA last week cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software.

Convatec offers design and manufacturing services for infusion set technologies and insertion devices for insulin pump treatment. Beta Bionics’ iLet uses its inset and contact detach infusion sets for subcutaneous insulin administration.

The company’s inset, an all-in-one infusion set with a built-in insertion device, connects to iLet on one end and the infusion site at the other. It features a soft, indwelling cannula. Convatec’s contact detach comes with a thin, stainless steel needle. Both infusion sets use kink-free infusion tubing to ensure uninterrupted insulin infusion. They also feature a …

Read more
  • 0

FDA clears automated insulin pump from Beta Bionics for type 1 diabetes

The FDA announced today that it cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software.

FDA clearance covers the devices for people 6 years of age and older with type 1 diabetes. Combined with a compatible, FDA-cleared integrated continuous glucose monitor (iCGM), they form the iLet Bionic Pancreas. Using an algorithm, the automated insulin delivery system determines and commands insulin delivery.

Interim CEO and board member Martha Aronson last year told Drug Delivery Business News recently that the iLet will help those with diabetes reduce the cognitive burden of managing their disease.

“Today’s action will provide the type 1 diabetes community with additional options and flexibilities for diabetes management and may help to broaden the reach of AID technology,” said Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health. “The FDA is committed to advancing new …

Read more
  • 0

The year ahead in diabetes care: what to expect in 2023

[Image courtesy of Walmart] After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023.

Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more.

You can read all about the biggest diabetes stories of 2022 here.

As we embark on a new year in 2023, there’s still plenty to look forward to in the diabetes space. Here are a few things worth keeping an eye on.

CMS decision could benefit CGMs

In October, The Centers for Medicare and Medicaid Services (CMS) published a new local coverage determination (LCD). That LCD modified coverage criteria for continuous glucose monitors (CGMs). The modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia.

Analysts suggested at the time that the decision marked a win for …

Read more
  • 0

Beta Bionics appoints new CMO as it prepares for artificial pancreas launch

Dr. Steven Russell. [Image courtesy of Beta Bionics]Beta Bionics announced that it appointed Dr. Steven Russell as its chief medical officer (CMO) as it readies itself for a major product launch.

Concord, Massachusetts-based Beta Bionics develops the iLet bionic pancreas system. The pocket-sized, wearable, investigational iLet device autonomously doses insulin. Worn like an insulin pump, iLet users only enter body weight to initialize therapy. Users would no longer have the need for insulin regimen parameters.

The company designed the device to then automatically titrate and infuse insulin. It eliminates the requirement of counting carbs, the settings of certain rates and factors and more.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Data supports Beta Bionics’ iLet bionic pancreas

Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c.

Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Beta Bionics looks to reduce ‘cognitive burden’ for those with diabetes with bionic pancreas

Beta Bionics’ iLet bionic pancreas offers insulin therapy without some of the hurdles associated with treating diabetes.

Users of insulin pumps may be used to a certain regimen associated with managing their diabetes. That can include carbohydrate counting, setting basal rates and more.

Beta Bionics has set out to change that. With the Concord, Massachusetts-based company’s iLet bionic pancreas, the user inputs just one number: their body weight.

The company designed the pocket-sized, wearable, investigational iLet device to autonomously dose insulin. Worn like an insulin pump, iLet users only enter body weight to initialize therapy without the need for insulin regimen parameters. The company designed the device to then automatically titrate and infuse insulin without requiring the counting of carbs, the settings of certain rates and factors and more.

“It’s very qualitative, not quantitative,” Beta Bionics interim CEO and board member Martha Aron…

Read more
  • 0